Regulating compounding pharmacies after NECC

New England Journal of Medicine

Volumn 367, Issue 21, 2012, Pages 1969-1972

  Outterson, Kevin ^a  

^a BOSTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; METHYLPREDNISOLONE ACETATE; SULFANILAMIDE; THALIDOMIDE;

DISASTER; DRUG EFFICACY; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; FUNGAL CONTAMINATION; FUNGAL MENINGITIS; HUMAN; PHARMACY; PRESCRIPTION; PRIORITY JOURNAL; REIMBURSEMENT; SHORT SURVEY;

EID: 84869401476     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp1212667     Document Type: Article

References (5)

1. Outterson K. Higher First Amendment hurdles for public health regulation. N Engl J Med 2011;365(7):e13.
2. Massachusetts Board of Registration in Pharmacy. New England Compounding Center (NECC): preliminary investigation findings. October 23, 2012 (http://www.mass.gov/eohhs/docs/dph/quality/boards/necc/necc-preliminary-report- 10-23-2012.pdf).
3. Boodoo JM. Compounding problems and compounding confusion: federal regulation of compounded drug products and the FDAMA circuit split. Am J Law Med 2010;36:220-47.
4. Carette S, Marcoux S, Truchon R, et al. A controlled trial of corticosteroid injections into facet joints for chronic low back pain. N Engl J Med 1991:325:1002-7.
5. Staal JB, de Bie RA, de Vet HC, Hildebrandt J, Nelemans P. Injection therapy for subacute and chronic low back pain: an updated Cochrane review. Spine 2009;34:49-59.